Guardant Health (GH)
(Real Time Quote from BATS)
$17.44 USD
+0.28 (1.63%)
Updated Apr 26, 2024 10:42 AM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GH 17.44 +0.28(1.63%)
Will GH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GH
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
GH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet
Other News for GH
Guardant Health assumed with a Buy at Craig-Hallum
Key Takeaways From Guardant Health Analyst Ratings
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
FDA Advisory Panel review of Guardant Health Shield Blood Test on May 23